查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1873985

抗凝血逆转药物市场

Anticoagulant Reversal Drugs Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

预计到2031年，抗凝血逆转药物市场规模将从2024年的14.3亿美元成长至24.4亿美元，2031年至2031年的年复合成长率（CAGR）为10.08%。创新产品的推出预计将成为抗凝血逆转药物市场的重要趋势。

抗凝血逆转药物市场分析

近年来，抗凝血药物在预防和治疗各种心血管疾病方面应用广泛，包括肺栓塞（PE）、深部静脉栓塞（DVT）、心房颤动（AF）、机械心臟瓣膜相关血栓形成以及急性冠状动脉综合症。然而，这些药物的广泛使用会带来大小出血的风险，可能导致住院和急诊。当患者接受包含抗凝血药物和抗血小板药物或双重抗血小板药物的合併治疗时，这种风险会更高。单独使用华法林和阿斯匹灵时，出血风险最高。因此，抗凝血逆转药物对于降低出血风险至关重要。心房颤动（AFib）盛行率的不断上升和卒中事件的增加预计将推动旨在改善患者预后的新疗法的研发。

抗凝血逆转药物市场概览

根据美国疾病管制与预防中心（CDC）统计，美国每年有超过45.4万人因心房颤动住院治疗，约15.8万人因此死亡。心房颤动的发生率随年龄增加而增加，而高血压在老年族群中也更为常见，约五分之一的心房颤动病例是由高血压引起的。预计未来十年，老年人口的成长将推动抗凝血逆转药物的需求增加。

战略洞察

抗凝血逆转药物市场的驱动因素与机会

神经退化性疾病和言语障碍发生率不断上升

抗凝血逆转药物在出血性中风的治疗中发挥着至关重要的作用，它们能够减少持续出血并促进组织恢復。卒中的发生率正在上升，尤其是在中低收入国家。根据卒中意识基金会报告，美国每年约有79.5万人发生卒中，导致超过14万人死亡。其中，约40%的卒中相关死亡病例发生在男性，60%发生在女性。 2021年5月发表在《姑息医学年鑑》（Annals of Palliative Medicine，APM）上的一项研究表明，对服用华法林的急性缺血性卒中（AIS）患者联合使用四因子凝血酶原复合物浓缩物、新鲜冰冻血浆和维生素K1，可改善其神经功能并成功逆转凝血功能。因此，卒中发病率的上升是抗凝血逆转药物市场的重要驱动因素。

新型抗凝血逆转药物研究活动日益增加所带来的机会

为应对心血管疾病（例如心房颤动）日益增长的盛行率，新型疗法的研究取得了快速进展，这推动了抗凝血逆转药物市场的成长。人们对各种心血管疾病的创新治疗方案的需求持续旺盛。例如，2020年7月发表在《血栓与止血杂誌》（Journal of Thrombosis and Haemostasis）上的一项题为“安德沙奈特α和四因子凝血酶原复合物浓缩物（4F-PCC）逆转利伐沙班和阿哌沙班相关颅内出血的评估”的研究，评估了内安德沙奈特α治疗的有效性。研究项目的增加正在促进药物研发，并为整个行业的市场扩张创造了有利可图的机会。

抗凝血逆转药物市场細項分析

抗凝血逆转药物市场分析按产品和配销通路进行细分。

  • 依产品划分，市场可分为凝血酶原复合物浓缩剂、维生素K、鱼精蛋白、氨甲环酸、伊达鲁西珠单抗和AndeXXa。 2023年，凝血酶原复合物浓缩剂占了最大的市场份额。
  • 就分销管道而言，市场分为医院药房、零售药房和其他管道，其中医院药房在 2023 年占据最大的市场份额。

抗凝血逆转药物市场的地理分析

抗凝血逆转药物市场报告的地理范围分为五个区域：北美、亚太、欧洲、中东和非洲以及南美和中美洲。

北美地区引领抗凝血逆转药物市场，其中美国是最大的市场。该地区的成长主要受心血管疾病（如心房颤动）盛行率上升、市场参与者的技术进步以及美国主要公司的存在所驱动，这些因素将进一步加速市场成长。此外，美国市场参与者的策略性倡议预计也将促进市场成长。例如，阿斯特捷利康于2023年6月向美国和欧盟提交了其药物Andexxa（安德沙奈特α）的完整监管申请，此前该药物已获得有条件批准。 Andexxa旨在快速逆转直接口服FXa抑制剂的抗凝血作用，其使用已获得15项以上国家和国际指南的支持，涵盖多个学科领域。阿斯特捷利康目前正在寻求该药物在美国的完全适应症批准。

抗凝血逆转药物市场报告范围

抗凝血逆转药物市场的最新发展

抗凝血逆转药物市场评估是透过收集一手和二手研究的定性和定量资料进行的，这些数据包括重要的企业出版物、协会资料和资料库。以下是言语和语言障碍市场的一些最新进展：

  • 阿斯特捷利康製药印度有限公司宣布，已获得印度中央药品标准控制组织（CDSCO）的批准，可以进口和销售安德沙奈特α（Andexanet Alfa）。安德沙奈特α是一种治疗与Xa因子（FXa）抑制剂相关的危及生命或难治性出血的有效药物。 （资料来源：阿斯特捷利康製药，新闻稿，2024）
  • 奥克塔製药美国公司宣布，其产品Balfaxar已获得美国食品药物管理局（FDA）批准。 Balfaxar是一种非活化的四因子凝血酶原复合物浓缩剂（4F-PCC），含有维生素K依赖性凝血因子：凝血因子II（凝血酶原）、凝血因子VII、凝血因子IX和凝血因子X，以及抗血栓蛋白C和S。 Balfaxar适用于因维生素K拮抗剂（VKA）治疗而导致后天性凝血因子缺乏的成人患者，这些患者需要紧急手术或介入治疗。 Balfaxar透过补充华法林治疗引起的凝血因子缺乏，帮助恢復血液凝固功能。 （资料来源：奥克塔製药美国公司，新闻稿，2023年）

抗凝血逆转药物市场报告的覆盖范围和交付成果

题为《抗凝血逆转药物市场规模及预测（2021-2031）》的报告对市场进行了全面分析，涵盖以下领域：

  • 涵盖范围内所有关键细分市场的全球、区域和国家层面的市场规模和预测
  • 市场动态，包括驱动因素、限制因素和关键机会
  • 未来主要趋势
  • 详细的PEST/波特五力模型与SWOT分析
  • 全球及区域市场分析，重点在于关键市场趋势、主要参与者、法规及最新发展。
  • 产业格局和竞争分析，包括市场集中度、热力图分析、主要参与者和最新发展动态
  • 深入的公司概况

目录

第一章：引言

第二章：抗凝血逆转药物市场及主要结论

第三章：研究方法

  • 覆盖范围
  • 二手研究
  • 初步研究

第四章：抗凝血逆转药物市场及市场概况

  • 概述
  • PEST分析
    • 北美和PEST分析
    • 欧洲和PEST分析
    • 亚太地区及PEST分析
    • 中东和非洲
    • 南美洲和中美洲
  • 专家意见

第五章：抗凝血逆转药物市场及主要市场动态

  • 市场驱动因素
    • 心房颤动（心房颤动）盛行率上升
    • 中风盛行率增加
  • 市场限制
    • 抗凝血逆转药物价格昂贵
  • 市场机会
    • 增加抗凝血逆转药物的研究活动
  • 未来趋势
    • 创新产品的开发与上市
  • 影响分析

第六章：抗凝血逆转药物市场及全球分析

  • 全球抗凝血逆转药物市场收入预测与分析
  • 全球抗凝血逆转药物市场（依地域划分）－预测与分析
  • 市场定位

第七章：抗凝血逆转药物市场及产品分类

  • 概述
  • 2024 年及 2031 年抗凝血逆转药物市场份额（按产品划分）
  • 凝血酶原复合物浓缩物
    • 概述
    • 凝血酶原复合物浓缩剂：抗凝血逆转药物市场及收入预测（至2031年）
  • 维生素K
    • 概述
    • 维生素K：抗凝血逆转药物市场及收入预测（至2031年）
  • 鱼精蛋白
    • 概述
    • 鱼精蛋白：抗凝血逆转药物市场及收入预测（至2031年）
  • 氨甲环酸
    • 概述
    • 氨甲环酸：抗凝血逆转药物市场及收入预测（至2031年）
  • 伊达鲁西珠单抗
    • 概述
    • 伊达鲁西珠单抗：抗凝血逆转药物市场及收入预测（至2031年）
  • 安德克萨
    • 概述
    • Andexxa：抗凝血逆转药物市场及收入预测（至2031年）

第八章：抗凝血逆转药物市场及配销通路

  • 概述
  • 2024 年及 2031 年抗凝血逆转药物市场份额（按配销通路划分）
  • 医院药房
    • 概述
    • 医院药局：抗凝血逆转药物市场及收入预测（至2031年）
  • 零售药局
    • 概述
    • 零售药局：抗凝血逆转药物市场及收入预测（至2031年）
  • 其他的
    • 概述
    • 其他：抗凝血逆转药物市场及收入预测（至2031年）

第九章：抗凝血逆转药物市场及地理分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 亚太其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十章：新冠肺炎疫情对全球抗凝血逆转药物市场的影响

  • 北美洲
  • 欧洲
  • 亚太
  • 中东和非洲
  • 南美洲和中美洲

第十一章：抗凝血逆转药物市场及产业概况

  • 概述
  • 市场中各公司采取的成长策略（%）
  • 有机发展
    • 概述
    • 公司进行的有机发展
  • 无机物发展
    • 概述
    • 公司进行的非有机成长

第十二章：公司简介

  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Octapharma AG
  • AMAG PHARMACEUTICALS, INC.
  • Fresenius Kabi AG
  • Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
  • CSL Limited
  • China Biologic Products, Inc
  • Grifols, S.A.
  • Shanghai RAAS Blood Products Co., Ltd.

第十三章：附录

简介目录
Product Code: TIPRE00004954

The Anticoagulant Reversal Drugs Market is anticipated to grow to US$ 2.44 billion by 2031, up from US$ 1.43 billion in 2024, reflecting a compound annual growth rate (CAGR) of 10.08% from 2031 to 2031. The introduction and launch of innovative products are expected to be significant trends in the anticoagulant reversal drugs market.

Analysis of the Anticoagulant Reversal Drugs Market

Recently, the use of anticoagulants has surged for the prevention and treatment of various cardiovascular issues, including pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), thrombosis related to mechanical heart valves, and acute coronary syndromes. However, the extensive use of these medications poses risks of both major and minor bleeding, which can lead to hospital admissions and emergency visits. This risk is heightened when patients are on combination therapies that include both anticoagulants and antiplatelet or dual antiplatelet therapies. Warfarin and aspirin, when used alone, present the highest bleeding risks. Consequently, anticoagulant reversal drugs are essential for mitigating bleeding risks. The increasing prevalence of atrial fibrillation (AFib) and rising stroke incidents are expected to drive the development of new treatments aimed at improving patient outcomes.

Overview of the Anticoagulant Reversal Drugs Market

According to the Centers for Disease Control and Prevention (CDC), over 454,000 hospitalizations related to AFib occur annually in the US, leading to approximately 158,000 deaths. The likelihood of developing AFib increases with age, and high blood pressure, which is also more prevalent in older populations, contributes to about 1 in 5 AFib cases. The growing elderly population is projected to boost the demand for anticoagulant reversal drugs over the next decade.

Strategic Insights

Drivers and Opportunities in the Anticoagulant Reversal Drugs Market

Increasing Incidence of Neurodegenerative Diseases and Speech Disorders

Anticoagulant reversal drugs play a crucial role in managing hemorrhagic strokes by reducing ongoing bleeding and facilitating tissue recovery. The prevalence of strokes is rising, particularly in low- and middle-income countries. The Stroke Awareness Foundation reports that approximately 795,000 people in the US experience a stroke each year, resulting in over 140,000 deaths. Of these, around 40% of stroke-related fatalities occur in men, while 60% are in women. A study published in the Annals of Palliative Medicine (APM) in May 2021 demonstrated that administering a combination of 4-factor prothrombin complex concentrate, fresh frozen plasma, and vitamin K1 to a patient on warfarin who suffered an acute ischemic stroke (AIS) resulted in neurological improvement and successful reversal of coagulation. Thus, the increasing incidence of strokes is a significant driver for the anticoagulant reversal drugs market.

Opportunities from Growing Research Activities in Novel Anticoagulant Reversal Drugs

Rapid advancements in research for new therapeutics to address the rising prevalence of cardiovascular diseases, such as atrial fibrillation, are propelling the growth of the anticoagulant reversal drugs market. There is a continuous demand for innovative treatment options for various cardiovascular conditions. For example, a study titled 'Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages,' published in July 2020 in the Journal of Thrombosis and Haemostasis, assessed the effectiveness of andexanet alfa in treating intracranial hemorrhages (ICH). The rise in research initiatives is enhancing drug discovery efforts and creating lucrative opportunities for market expansion across the sector.

Segmentation Analysis of the Anticoagulant Reversal Drugs Market

The analysis of the anticoagulant reversal drugs market is segmented by product and distribution channel.

  • By product, the market is categorized into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, and AndeXXa. The prothrombin complex concentrates segment accounted for the largest market share in 2023.
  • Regarding distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and others, with hospital pharmacies holding the largest market share in 2023.

Geographical Analysis of the Anticoagulant Reversal Drugs Market

The geographical scope of the anticoagulant reversal drugs market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America leads the anticoagulant reversal drugs market, with the US being the largest market. The growth in this region is primarily driven by the increasing prevalence of cardiovascular diseases such as atrial fibrillation, advancements by market players, and the presence of major companies in the US, which will further accelerate market growth. Additionally, strategic initiatives by market players in the US are expected to enhance market growth. For instance, in June 2023, AstraZeneca submitted full regulatory filings for its Andexxa (andexanet alfa) in the US and EU, progressing from its current conditional approval. Andexxa is designed to rapidly reverse the anticoagulation effects of direct oral FXa inhibitors, and its use is supported by over 15 national and international guidelines across various disciplines. AstraZeneca is now pursuing full label approval in the US.

Scope of the Anticoagulant Reversal Drugs Market Report

Recent Developments in the Anticoagulant Reversal Drugs Market

The anticoagulant reversal drugs market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments in the market for speech and language disorders:

  • AstraZeneca Pharma India Ltd. announced that it received approval from the Central Drugs Standard Control Organisation (CDSCO) in India to import and market Andexanet Alfa, a treatment effective for life-threatening or refractory bleeding associated with Factor Xa (FXa) inhibitors. (Source: AstraZeneca Pharma, Press Release, 2024)
  • Octapharma USA announced the FDA approval of Balfaxar, a non-activated four-factor prothrombin complex concentrate (4F-PCC) containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, along with antithrombotic Proteins C and S. Balfaxar is indicated for urgent reversal of acquired coagulation factor deficiency due to vitamin K antagonist (VKA) therapy in adult patients requiring urgent surgery or invasive procedures, helping to restore blood coagulation by replenishing deficient clotting factors caused by warfarin therapy. (Source: Octapharma USA, Inc, Press Release, 2023)

Coverage and Deliverables of the Anticoagulant Reversal Drugs Market Report

The report titled "Anticoagulant Reversal Drugs Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics, including drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis highlighting key market trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
  • In-depth company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Anticoagulant Reversal Drugs Market and By Product
    • 1.3.2 Global Anticoagulant Reversal Drugs Market and By Distribution Channel
    • 1.3.3 Global Anticoagulant Reversal Drugs Market and By Geography

2. Anticoagulant Reversal Drugs Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Anticoagulant Reversal Drugs Market and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America and PEST Analysis
    • 4.2.2 Europe and PEST Analysis
    • 4.2.3 Asia Pacific and PEST Analysis
    • 4.2.4 Middle East and Africa
    • 4.2.5 South and Central America
  • 4.3 Expert Opinion

5. Anticoagulant Reversal Drugs Market and Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rise in Prevalence of Atrial Fibrillation (AFib)
    • 5.1.2 Increase in Prevalence of Stroke
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Anticoagulant Reversal Drugs
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Research Activities on Anticoagulant Reversal Drugs
  • 5.4 Future Trends
    • 5.4.1 Development and Launch of Innovative Products
  • 5.5 Impact Analysis

6. Anticoagulant Reversal Drugs Market and Global Analysis

  • 6.1 Global Anticoagulant Reversal Drugs Market Revenue Forecast And Analysis
  • 6.2 Global Anticoagulant Reversal Drugs Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning

7. Anticoagulant Reversal Drugs Marketand By Product

  • 7.1 Overview
  • 7.2 Anticoagulant Reversal Drugs Market Share, by Product, 2024 and 2031 (%)
  • 7.3 Prothrombin Complex Concentrates
    • 7.3.1 Overview
    • 7.3.2 Prothrombin Complex Concentrates: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.4 Vitamin K
    • 7.4.1 Overview
    • 7.4.2 Vitamin K: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.5 Protamine
    • 7.5.1 Overview
    • 7.5.2 Protamine: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.6 Tranexamic Acid
    • 7.6.1 Overview
    • 7.6.2 Tranexamic Acid: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.7 Idarucizumab
    • 7.7.1 Overview
    • 7.7.2 Idarucizumab: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 7.8 Andexxa
    • 7.8.1 Overview
    • 7.8.2 Andexxa: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)

8. Anticoagulant Reversal Drugs Marketand By Distribution Channel

  • 8.1 Overview
  • 8.2 Anticoagulant Reversal Drugs Market Share, by Distribution Channel, 2024 and 2031 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 8.4 Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Retail Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)

9. Anticoagulant Reversal Drugs Market and Geographic Analysis

  • 9.1 North America: Anticoagulant Reversal Drugs Market
    • 9.1.1 Overview
    • 9.1.2 North America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
    • 9.1.3 North America: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
    • 9.1.4 North America: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2024 and 2031 (USD Million)
    • 9.1.5 North America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.1.6 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.6.1 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.6.2 US: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
      • 9.1.6.3 US: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
    • 9.1.7 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.7.1 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.7.2 Canada: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
      • 9.1.7.3 Canada: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
    • 9.1.8 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.8.1 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.1.8.2 Mexico: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
      • 9.1.8.3 Mexico: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
  • 9.2 Europe: Anticoagulant Reversal Drugs Market
    • 9.2.1 Overview
    • 9.2.2 Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
    • 9.2.3 Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.2.4 Europe: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.5 Europe: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.2.6 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.6.1 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.6.2 Germany: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.6.3 Germany: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.7 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.7.1 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.7.2 France: Anticoagulant Reversal Drugs Market, by Productand Revenue and Forecast to 2031 (USD Million)
      • 9.2.7.3 France: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.8 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.8.1 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.8.2 UK: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.8.3 UK: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.9 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.9.1 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.9.2 Italy: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.9.3 Italy: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.10 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.10.1 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.10.2 Spain: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.10.3 Spain: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.2.11 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.11.1 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.2.11.2 Rest of Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.2.11.3 Rest of Europe: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 9.3 Asia Pacific: Anticoagulant Reversal Drugs Market
    • 9.3.1 Overview
    • 9.3.2 Asia Pacific: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (USD Million)
    • 9.3.3 Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.3.4 Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.5 Asia Pacific: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.3.6 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.6.1 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.6.2 China: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.6.3 China: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.7 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.7.1 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.7.2 Japan: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.7.3 Japan: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.8 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.8.1 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.8.2 India: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.8.3 India: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.9 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.9.1 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.9.2 South Korea: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.9.3 South Korea: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.10 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.10.1 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.10.2 Australia: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.10.3 Australia: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.3.11 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.11.1 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.3.11.2 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.3.11.3 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 9.4 Middle East and Africa: Anticoagulant Reversal Drugs Market
    • 9.4.1 Overview
    • 9.4.2 Middle East and Africa: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    • 9.4.3 Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.4.4 Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.4.5 Middle East and Africa: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.4.6 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.6.1 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.6.2 Saudi Arabia Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.6.3 Saudi Arabia Anticoagulant Reversal Drugs Market, Type and Revenue and Forecast to 2031 (USD Million)
    • 9.4.7 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.7.1 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.7.2 UAE Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.7.3 UAE Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.4.8 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.8.1 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.8.2 South Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.8.3 South Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.4.9 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.9.1 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.4.9.2 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.4.9.3 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 9.5 South and Central America: Anticoagulant Reversal Drugs Market
    • 9.5.1 Overview
    • 9.5.2 South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
    • 9.5.3 South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
    • 9.5.4 South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.5.5 South and Central America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
    • 9.5.6 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.6.1 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.6.2 Brazil: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.5.6.3 Brazil: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.5.7 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.7.1 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.7.2 Argentina: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.5.7.3 Argentina: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 9.5.8 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.8.1 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
      • 9.5.8.2 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
      • 9.5.8.3 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)

10. Impact of COVID-19 Pandemic on Global Anticoagulant Reversal Drugs Market

  • 10.1 North America: Impact Assessment of COVID-19 Pandemic
  • 10.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
  • 10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
  • 10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Anticoagulant Reversal Drugs Marketand Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies Done by the Companies in the Market, (%)
  • 11.3 Organic Developments
    • 11.3.1 Overview
    • 11.3.2 Organic Developments Done By Companies
  • 11.4 Inorganic Developments
    • 11.4.1 Overview
    • 11.4.2 Inorganic Developments Done By Companies

12. Company Profiles

  • 12.1 Boehringer Ingelheim International GmbH
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc.
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Octapharma AG
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 AMAG PHARMACEUTICALS, INC.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Fresenius Kabi AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 CSL Limited
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 China Biologic Products, Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Grifols, S.A.
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Shanghai RAAS Blood Products Co., Ltd.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 Glossary of Terms